From the annual report in prep of the annual August shareholders proxy vote:
Notable Developments in Fiscal 2021 and Subsequent:
• 6/20 New preclinical data supporting SM-88 mechanism presented at AACR
• 6/20 Preclinical data demonstrating anti-cancer effect of TYME-18 presented at AACR
• 8/20 SM-88 granted Orphan Drug Designation from FDA for potential treatment of patients with pancreatic cancer
• 8/20 Outcome of interim futility review for HopES sarcoma Phase 2 study announced
• 8/20 TYME-19 announced as potential treatment for COVID-19
• 9/20 Phase 2 prostate cancer study published in the Journal Investigation New Drugs
*********************
• 11/20 Richie Cunningham appointed as Chief Executive Officer
• 2/21 Completed $100 million Registered Direct Offering
*********************
FY 22
• 4/21 Dr. Jan M. Van Tornout appointed as acting Chief Medical Officer
• 5/21 Frank L. Porfido appointed as Chief Financial Officer, effective June 2021
The quick turnaround from November 2020 --> February 21
.....with Rich Cunningham put in CEO seat and then the
.....$100 Million funding finally completed, the investors on
.....the funding had Cunningham hand-picked
....well before the buy-in.
May be the reason for Hoffman (founder) stepping down. Hoffman was very visible in June 10th telecon. Honestly, disappointed in the proxy sample ballot being limited to standard auditing company, couple other items of no real impact like voting on a buyout (sigh) or a reverse split (whew).
Neither in the cards at this time. Here's an excerpt from Cunningham's statement early on in the annual report:
*******************************
I can say with a high degree of confidence that TYME is positioned to capitalize on the significant opportunities before it and create significant value for our stakeholders.
I deeply believe that our novel candidates have great potential to make a profound difference in the lives of people we aim to help in the years to come. On behalf of the entire team at TYME, I would like to thank you for your interest and support.
Richie Cunningham
Chief Executive Officer
*************************************
VR, and Good Luck to All
